Novavax stock rallies 9.53% and outperforms rivals

11 articles · Updated · MarketWatch · May 8

Shares closed at $10.11 on Friday as trading volume jumped to 13.3 million, far above the 50-day average of 4.6 million.
The gain came during a broader market rise, with the Nasdaq Composite up 1.71% to 26,247.08 and the Dow Jones Industrial Average edging 0.02% higher.
Novavax still ended 15.54% below its 52-week high of $11.97 reached on 26 February, while Johnson & Johnson, Pfizer and Merck all fell.

After a 9.5% stock surge, are cost-cutting and new deals enough to fuel a genuine long-term recovery for Novavax?

Can Novavax's better side-effect profile truly challenge the dominance of mRNA vaccines in a shrinking market?

Is Novavax's pivot to a partnership model a masterstroke for survival or a risky gamble on the success of its rivals?